WGS

WGS

USD

GeneDx Holdings Corp. Class A Common Stock

$139.485+4.575 (3.391%)

Echtzeitkurs

Healthcare
Diagnostics & Research
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$134.910

Hoch

$141.750

Tief

$134.000

Volumen

0.68M

Unternehmensfundamentaldaten

Marktkapitalisierung

4.0B

Branche

Diagnostics & Research

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.58M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $55.17Aktuell $139.485Hoch $146

Ähnliche Nachrichten

Analyst Upgrades

Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140

Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings with a Equal-Weight and raises the price target from $95 to $140.

Mehr anzeigen
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140
Analyst Upgrades

Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings with a Buy and raises the price target from $155 to $160.

Mehr anzeigen
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160
Analyst Upgrades

Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings with a Buy and raises the price target from $115 to $170.

Mehr anzeigen
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170
Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $140 to $165.

Mehr anzeigen
BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165
BusinessWire

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume growth to 33% year-over-year Expanded adjusted gross

Mehr anzeigen
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
PR Newswire

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating...

Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $140

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $125 to $140.